{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:27Z","timestamp":1791397347680,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MSD Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10198-019-01044-3","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T05:10:20Z","timestamp":1553145020000},"page":"829-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Economic burden of HPV9-related diseases: a real-world cost analysis from Italy"],"prefix":"10.1007","volume":"20","author":[{"given":"F. S.","family":"Mennini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-4810","authenticated-orcid":false,"given":"Gianluca","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Favato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sciattella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"1","key":"1044_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/infdis\/jiq016","volume":"203","author":"S Goldstone","year":"2011","unstructured":"Goldstone, S., et al.: Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J. Infect. Dis. 203(1), 66\u201374 (2011)","journal-title":"J. Infect. Dis."},{"key":"1044_CR2","volume-title":"Prevalence of HPV in adults aged 18-69: United States, 2011\u20132014","author":"GM McQuillan","year":"2017","unstructured":"McQuillan, G.M., et al.: Prevalence of HPV in adults aged 18-69: United States, 2011\u20132014. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD (2017)"},{"issue":"7","key":"1044_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.clinthera.2013.05.003","volume":"35","author":"G Favato","year":"2013","unstructured":"Favato, G., et al.: A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy. Clin. Ther. 35(7), 904\u2013914 (2013)","journal-title":"Clin. Ther."},{"issue":"1","key":"1044_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","author":"GM Clifford","year":"2003","unstructured":"Clifford, G.M., et al.: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88(1), 63\u201373 (2003)","journal-title":"Br. J. Cancer"},{"issue":"1","key":"1044_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers, J.M., et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12\u201319 (1999)","journal-title":"J. Pathol."},{"issue":"4 Suppl","key":"1044_CR6","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","volume":"46","author":"AK Chaturvedi","year":"2010","unstructured":"Chaturvedi, A.K.: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J. Adolesc. Health 46(4 Suppl), S20\u2013S26 (2010)","journal-title":"J. Adolesc. Health"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/oxfordjournals.epirev.a036020","volume":"10","author":"LA Koutsky","year":"1988","unstructured":"Koutsky, L.A., Galloway, D.A., Holmes, K.K.: Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10, 122\u2013163 (1988)","journal-title":"Epidemiol. Rev."},{"issue":"7","key":"1044_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/archotol.125.7.743","volume":"125","author":"LR Armstrong","year":"1999","unstructured":"Armstrong, L.R., Derkay, C.S., Reeves, W.C.: Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch. Otolaryngol. Head Neck Surg. 125(7), 743\u2013748 (1999)","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"1","key":"1044_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1086\/313914","volume":"31","author":"LR Armstrong","year":"2000","unstructured":"Armstrong, L.R., et al.: Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis. 31(1), 107\u2013109 (2000)","journal-title":"Clin. Infect. Dis."},{"key":"1044_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"S Hartwig","year":"2015","unstructured":"Hartwig, S., Baldauf, J.J., Dominiak-Felden, G.: Estimation of the epidemiological burden of HPV-related cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent compared to first generation HPV vaccines. Papillomavirus Res 1, 90\u2013100 (2015)","journal-title":"Papillomavirus Res"},{"key":"1044_CR11","unstructured":"FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 12\/11\/2014, 12 Aug 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426485.htm (2014)"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"a769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit, M., Choi, Y.H., Edmunds, W.J.: Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008)","journal-title":"BMJ"},{"issue":"8","key":"1044_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"359","author":"JJ Kim","year":"2008","unstructured":"Kim, J.J., Goldie, S.J.: Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359(8), 821\u2013832 (2008)","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"1044_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/MLR.0b013e318269e06d","volume":"50","author":"G Favato","year":"2012","unstructured":"Favato, G., et al.: Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study. Med. Care 50(12), 1076\u20131085 (2012)","journal-title":"Med. Care"},{"issue":"11","key":"1044_CR15","doi-asserted-by":"publisher","first-page":"e49699","DOI":"10.1371\/journal.pone.0049699","volume":"7","author":"G Baio","year":"2012","unstructured":"Baio, G., et al.: Economic burden of human papillomavirus-related diseases in Italy. PLoS One 7(11), e49699 (2012)","journal-title":"PLoS One"},{"key":"1044_CR16","unstructured":"Ministero della Salute: Piano Nazionale Prevenzione Vaccinale 2017\u20132019. http:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_2_1.jsp?id=2571"},{"issue":"2","key":"1044_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2010.06.025","volume":"119","author":"G Ferrandina","year":"2010","unstructured":"Ferrandina, G., et al.: Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol. Oncol. 119(2), 243\u2013249 (2010)","journal-title":"Gynecol. Oncol."},{"issue":"Suppl 1","key":"1044_CR18","doi-asserted-by":"publisher","first-page":"A54","DOI":"10.1016\/j.vaccine.2009.02.052","volume":"27","author":"FS Mennini","year":"2009","unstructured":"Mennini, F.S., et al.: Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine 27(Suppl 1), A54\u2013A61 (2009)","journal-title":"Vaccine"},{"key":"1044_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2458-9-71","volume":"9","author":"P Giorgi Rossi","year":"2009","unstructured":"Giorgi Rossi, P., et al.: Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 9, 71 (2009)","journal-title":"BMC Public Health"},{"issue":"2","key":"1044_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.09.031","volume":"112","author":"FS Mennini","year":"2009","unstructured":"Mennini, F.S., et al.: Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol. Oncol. 112(2), 370\u2013376 (2009)","journal-title":"Gynecol. Oncol."},{"key":"1044_CR21","unstructured":"Salute, M.: Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di raibilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 2013, Pubblicato sulla GURI N. 23 del 28\/01\/2013 Suppl. n. 8"},{"issue":"11","key":"1044_CR22","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1185\/03007990802485694","volume":"24","author":"M Merito","year":"2008","unstructured":"Merito, M., et al.: Treatment patterns and associated costs for genital warts in Italy. Curr. Med. Res. Opin. 24(11), 3175\u20133183 (2008)","journal-title":"Curr. Med. Res. Opin."},{"key":"1044_CR23","unstructured":"Istat: https:\/\/rivaluta.istat.it (2018). Accessed Jan 2019"},{"issue":"2","key":"1044_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40261-017-0597-x","volume":"38","author":"FS Mennini","year":"2018","unstructured":"Mennini, F.S., et al.: Burden of disease of human papillomavirus (HPV): hospitalizations in the Marche and Veneto regions. An observational study. Clin. Drug Investig. 38(2), 173\u2013180 (2018)","journal-title":"Clin. Drug Investig."},{"issue":"7","key":"1044_CR25","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., et al.: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009)","journal-title":"PLoS Med."},{"issue":"2","key":"1044_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF03320660","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore, G.: Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEcon. Ital. Res. Artic. 11(2), 83\u201393 (2009)","journal-title":"PharmacoEcon. Ital. Res. Artic."},{"issue":"8","key":"1044_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/archotol.126.8.935","volume":"126","author":"D Bishai","year":"2000","unstructured":"Bishai, D., Kashima, H., Shah, K.: The cost of juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 126(8), 935\u2013939 (2000)","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"5","key":"1044_CR28","doi-asserted-by":"publisher","first-page":"500e1","DOI":"10.1016\/j.ajog.2008.03.064","volume":"198","author":"D Hu","year":"2008","unstructured":"Hu, D., Goldie, S.: The economic burden of noncervical human papillomavirus disease in the United States. Am. J. Obstet. Gynecol. 198(5), 500e1\u2013500e7 (2008)","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1044_CR29","unstructured":"Istituto Nazionale di Statistica (ISTAT): Popolazione residente al 1 Gennaio 2018. Statistiche Demografiche (2018). http:\/\/demo.istat.it\/ . Accessed Jan 2019"},{"key":"1044_CR30","unstructured":"AIOM, A.: I numeri del cancro in Italia 2017. I.P.S. Editore, Editor (2017)"},{"issue":"13","key":"1044_CR31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","volume":"51","author":"B Serrano","year":"2015","unstructured":"Serrano, B., et al.: Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur. J. Cancer 51(13), 1732\u20131741 (2015)","journal-title":"Eur. J. Cancer"},{"key":"1044_CR32","unstructured":"WHO, I., Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Italy, I. Summary Report, Editor (2017)"},{"key":"1044_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/1471-2407-12-533","volume":"12","author":"B Garcia-Espinosa","year":"2012","unstructured":"Garcia-Espinosa, B., Moro-Rodriguez, E., Alvarez-Fernandez, E.: Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer 12, 533 (2012)","journal-title":"BMC Cancer"},{"key":"1044_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2407-12-30","volume":"12","author":"S Hartwig","year":"2012","unstructured":"Hartwig, S., et al.: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 12, 30 (2012)","journal-title":"BMC Cancer"},{"key":"1044_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/1471-2407-14-968","volume":"14","author":"S Abogunrin","year":"2014","unstructured":"Abogunrin, S., et al.: Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer 14, 968 (2014)","journal-title":"BMC Cancer"},{"issue":"6","key":"1044_CR36","doi-asserted-by":"publisher","first-page":"djv403","DOI":"10.1093\/jnci\/djv403","volume":"108","author":"X Castellsague","year":"2016","unstructured":"Castellsague, X., et al.: HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J. Natl. Cancer Inst. 108(6), djv403 (2016)","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"1044_CR37","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jcp.2008.063149","volume":"62","author":"C Miralles-Guri","year":"2009","unstructured":"Miralles-Guri, C., et al.: HPV prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62(10), 870\u2013878 (2009)","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"1044_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijporl.2009.09.004","volume":"74","author":"AJ Donne","year":"2010","unstructured":"Donne, A.J., et al.: The role of HPV type in Recurrent Respiratory Papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 74(1), 7\u201314 (2010)","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"issue":"6","key":"1044_CR39","first-page":"375","volume":"34","author":"M Fusconi","year":"2014","unstructured":"Fusconi, M., et al.: Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol. Ital. 34(6), 375\u2013381 (2014)","journal-title":"Acta Otorhinolaryngol. Ital."},{"issue":"Suppl 3","key":"1044_CR40","first-page":"S3\/35","volume":"24","author":"CJ Lacey","year":"2006","unstructured":"Lacey, C.J., Lowndes, C.M., Shah, K.V.: Chap. 4: Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease. Vaccine 24(Suppl 3), S3\/35\u2013S41 (2006)","journal-title":"Vaccine"},{"key":"1044_CR41","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation. Handbooks in health economic evaluation series","author":"AH Briggs","year":"2006","unstructured":"Briggs, A.H., Claxton, K., Sculpher, M.J.: Decision modelling for health economic evaluation. Handbooks in health economic evaluation series. Oxford University Press, Oxford (2006) (x, 237, ill.; 24 cm)"},{"issue":"November 2017","key":"1044_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.techfore.2016.05.016","volume":"124","author":"G Favato","year":"2017","unstructured":"Favato, G., Vecchiato, R.: Embedding real options in scenario planning: a new methodological approach. Technol. Forecast. Soc. Change 124(November 2017), 135\u2013149 (2017)","journal-title":"Technol. Forecast. Soc. Change"},{"issue":"5","key":"1044_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1524-4733.2007.00302.x","volume":"11","author":"B Brown","year":"2008","unstructured":"Brown, B., et al.: An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 11(5), 791\u2013799 (2008)","journal-title":"Value Health"},{"issue":"4","key":"1044_CR44","first-page":"958","volume":"19","author":"A Mandic","year":"2014","unstructured":"Mandic, A., Usaj Knezevic, S., Kapicl, T., Ivkovic: Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer. J BUON 19(4), 958\u2013964 (2014)","journal-title":"J BUON"},{"issue":"4","key":"1044_CR45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1634\/theoncologist.2002-0342","volume":"7","author":"M Friedlander","year":"2002","unstructured":"Friedlander, M., Grogan, M., Force, U.S.P.S.T.: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7(4), 342\u2013347 (2002)","journal-title":"Oncologist"},{"issue":"10103","key":"1044_CR46","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari, K.S., et al.: Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103), 1654\u20131663 (2017)","journal-title":"Lancet"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-019-01044-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T20:36:03Z","timestamp":1721075763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-019-01044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s10198-019-01044-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"17 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}